Cardiac involvement and presenting dFLC (difference between involved and uninvolved free light chains) are independent predictors of outcome in systemic AL amyloidosis. These markers have limited prognostic utility in patients surviving the initial months following diagnosis. Here we assessed immunoparesis, as determined by novel heavy+light chain (HLC) immunoassays, as a prognostic marker for survival in AL amyloidosis. HLC measurements identified immunoparesis of at least one immunoglobulin (Ig) isotype in 145 (85%) patients; and severe immunoparesis (≥2 Ig isotypes suppressed by >50% below normal levels) in 29 (17%) patients. Median overall survival (OS) on intention to treat (ITT) analysis was 26Á2 months. In the ITT cohort, dFLC >180 mg/l was associated with shorter OS (P = 0Á05); whereas HLC immunoparesis was not prognostic. On a landmark analysis of 127 patients alive at 6 months, presenting dFLC was not prognostic for OS (P = 0Á33) and severe HLC immunoparesis trended towards poorer survival (20Á2 vs. 42Á8 months; P = 0Á09). In the subset of patients with cardiac involvement, severe HLC immunoparesis conferred very poor outcome (median OS 8Á8 vs. 29Á9 months, P = 0Á007). In conclusion, severe HLC immunoparesis is an independent marker of long-term poor prognosis in AL patients with cardiac involvement. The pathophysiological significance of this observation needs further study.
Summary
Cardiac involvement and presenting dFLC (difference between involved and uninvolved free light chains) are independent predictors of outcome in systemic AL amyloidosis. These markers have limited prognostic utility in patients surviving the initial months following diagnosis. Here we assessed immunoparesis, as determined by novel heavy+light chain (HLC) immunoassays, as a prognostic marker for survival in AL amyloidosis. HLC measurements identified immunoparesis of at least one immunoglobulin (Ig) isotype in 145 (85%) patients; and severe immunoparesis (≥2 Ig isotypes suppressed by >50% below normal levels) in 29 (17%) patients. Median overall survival (OS) on intention to treat (ITT) analysis was 26Á2 months. In the ITT cohort, dFLC >180 mg/l was associated with shorter OS (P = 0Á05); whereas HLC immunoparesis was not prognostic. On a landmark analysis of 127 patients alive at 6 months, presenting dFLC was not prognostic for OS (P = 0Á33) and severe HLC immunoparesis trended towards poorer survival (20Á2 vs. 42Á8 months; P = 0Á09). In the subset of patients with cardiac involvement, severe HLC immunoparesis conferred very poor outcome (median OS 8Á8 vs. 29Á9 months, P = 0Á007). In conclusion, severe HLC immunoparesis is an independent marker of long-term poor prognosis in AL patients with cardiac involvement. The pathophysiological significance of this observation needs further study.
Keywords: hevylite, immunoparesis, amyloid, cardiac, freelite.
Systemic light chain amyloidosis (AL amyloidosis) is a rare disorder of misfolded monoclonal immunoglobulin (Ig) free light chains (FLC), which result in insoluble fibrils deposition in organs causing progressive organ dysfunction. The amyloidogenic FLC are products of an underlying B cell clonal disorder (usually a plasma cell clone) and current therapeutic strategies are aimed at targeting such clones to reduce the levels of circulating clonal FLC. The prognosis in a patient with systemic AL amyloidosis depends on the extent of end organ damage -particularly cardiac impairment. Additionally, the level of circulating FLC also has independent prognostic significance (Dispenzieri et al, 2009; Comenzo et al, 2012; Kumar et al, 2012; Palladini et al, 2012) , as has achieving a deep biochemical response to therapy. A substantial proportion of patients (up to 30% in some series) succumb prematurely to disease-related complications, primarily due to advanced cardiac involvement (Dispenzieri et al, 2004) . Hence the prognostic factors in early survivors (i.e. outcomes on landmark analyses) are very different from those of 'intention to treat analysis' at baseline. The value of current amyloidosis staging systems in assessing longer term prognosis of patients surviving past the initial few months remains unclear and appears to be limited.
In addition to free light chains, monoclonal intact immunoglobulins (M-Igs) are also expressed in about 50-75% of patients with AL amyloidosis, although levels are measurable for monitoring purposes only in about 25% of patients (Lachmann et al, 2003) . The prognostic value of an intact M-Ig in systemic AL amyloidosis is unclear, with some series reporting poorer outcomes for patients expressing intact immunoglobulins (Kumar et al, 2010 (Kumar et al, , 2011 . Alternatively, and similar to other plasma cell dyscrasias, systemic immunoparesis has recently been associated with poorer outcomes in AL amyloidosis patients (Muchtar et al, 2016a) .
Novel serum assays allow quantification of Ig'j and Ig'k heavy+light chains (HLC) from which Ig'j/Ig'k HLC ratios can be derived. This may give an indication of clonality and HLC immunoassays appear to be sensitive for identifying and quantifying levels of M-Ig in plasma cell dyscrasias (Bijzet et al, 2012; Sch€ onland et al, 2012; Ludwig et al, 2013) . The particular advantage of HLC immunoassays over traditional methods of Ig measurements is that it allows the quantification of the uninvolved (non-clonal) member of the pair as well as of the other Ig classes (e.g., in an IgGj monoclonal protein expressing patient, levels of IgGk, IgAj, IgAk, IgMj and IgMk may be measured) -thus providing an accurate measurement of isotype and non-isotype specific Ig values as well as pair immunosuppression.
There are few studies evaluating the role of HLC suppression for prognostication in plasma cell dyscrasias. In myeloma, HLC suppression appears to predict for poorer outcomes (Avet-Loiseau et al, 2011; Harutyunyan et al, 2016; Ludwig et al, 2016) . Here we report the significance of immunoparesis as determined by HLC suppression in a population of newly diagnosed patients with systemic AL amyloidosis.
Methods
The study included unselected patients with AL amyloidosis seen at the National Amyloidosis Centre in London between 2003 and 2008, with serum samples collected at the time of presentation, prior to any therapy, and stored at À80°C. A total of 170 patients with systemic AL amyloidosis were included. There was no blinding in the study. Diagnosis of amyloidosis was confirmed in all cases with a tissue biopsy demonstrating characteristic birefringence on Congo red staining. Typing of AL amyloidosis was confirmed by immunohistochemical staining with appropriate antibodies and by exclusion of hereditary amyloidosis, where necessary, by genetic sequencing of the genes implicated. Patients fulfilling criteria for symptomatic myeloma were excluded. All patients underwent systematic review at presentation and detailed follow-up assessments at 6-monthly intervals or as clinically indicated. Assessment included clinical examination, detailed blood and urine analysis (including assessment of serum and urine monoclonal Ig and serum free light chains), serial 123 I-labelled serum amyloid P component (SAP) scintigraphy to assess whole body amyloid load, electrocardiogram (ECG) and echocardiogram. Organ involvement was defined according to the international amyloidosis consensus criteria (Gertz et al, 2004a) . Patients were treated with chemotherapy regimens used to treat myeloma during the study period. Table SI ). Moderate immunoparesis was defined as at least two Ig isotypes suppressed below the lower limit of normal, and severe immunoparesis was defined as levels of two or more isotypes suppressed by 50% or greater below the lower limit of normal. Survival studies were performed on 163 patients with available follow-up data (median follow-up 35 months (2Á4-85Á3 months). Cardiac involvement for survival studies was defined according to the international amyloidosis consensus criteria (Gertz et al, 2004a) and/or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) >332 ng/l. There were 108 deaths, of which 8 were due to infection and 89 due to amyloidosis. Differences in overall survival (OS) between patient groups were analysed using Kaplan-Meier survival curves with the log rank test used to indicate significance. The association of variables with OS was performed with Cox proportional hazard model. A landmark analysis was carried out in patients surviving 6 months from study entry. P values were two-tailed with a significance level of 0Á05. Statistical analyses were performed using SPSS v21 (IBM Corp., Armonk, NY, USA). Statistical differences for categorical values were calculated using the chi-square (v 2 ) test. Survival graphs were generated using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). The study was carried out in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, and was approved by the institutional review board. All participating patients provided written informed consent.
Results
Baseline characteristics including demographics, clinical features and serum biomarkers for 170 AL amyloidosis patients are presented in Table I : 73% and 63% had cardiac and renal involvement, respectively. None of the patients had symptomatic myeloma but 21% had greater than 10% bone marrow plasma cell infiltration. The association of baseline variables with HLC and total Ig immunoparesis is presented in Table I; and in Tables SII and SIII for moderate and severe immunoparesis, respectively. Our analyses mainly revealed an association between any degree of immunoparesis and an abnormal serum j/k FLC ratio. (56) 77 (53) 19 (76) 0Á03 61 (53) 31 (61) 0Á35 Male 104 (61) 92 (63) 12 (48) 0Á14 73 (64) 29 (57) 0Á42 Cardiac involvement* 124 (73) 106 (73) 18 (72) 0Á91 86 (75) 35 (69) 0Á41 Kidney involvement
104 (63) 91 (64) 13 (57) 0Á51 72 (63) 31 (66) 0Á69 Liver involvement
45 (27) 39 (27) 6 (27) 1Á00 27 (24) 16 ( (10) 15 (11) 1 (4) 0Á33 12 (11) 4 (8)
0Á64
>1 organ involved 66 (39) 58 (40) 8 (32) 0Á45 44 (38) 21 ( (79) 119 (82) 15 (60) 0Á01 99 (86) 31 ( (63) 18/31 (58)
Abnormal HLC ratio † 110 (65) 96 (66) 14 (56) 0Á32 74 (64) 34 (68) 0Á77 Intact M-Ig (by IFE)
87 (51) 78 (54) 9 (36) 0Á10 57 (50) 28 (55) 0Á53 n = 109
60 (55) 55 (58) 5 (36) 43 (55) 16 (55) Melphalan based 22 (20) 19 (20) 3 (21) 16 (21) 6 (21) VAD 4 (4) 4 (4) 0 (0) 4 (5) 0 (0) Other 15 (14) 12 (13) 3 (21) 10 (13) 4 (14) dFLC, difference between involved and uninvolved free light chains; GI, gastrointestinal; HLC, heavy+light chain; IFE, immunofixation electrophoresis; Ig, immunoglobulin; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PNS, peripheral nervous system; sFLC, serum free light chain; VAD, vincristine, doxorubicin and dexamethasone. *Determined by presence of cardiac amyloid deposits and/or NT-proBNP>332 ng/l. † 3 patients had more than one Ig class with an abnormal HLC ratio. ‡ n = 109 patients with treatment data. § 4 patients had missing Ig data. (Table II) .
HLC Suppression in AL Amyloidosis
Total Ig measurements identified immunoparesis of at least one of any IgG, IgA and IgM in 115/166 (69%) patients, all of which were identified by HLC suppression. 56/166 (34%) patients had two or more immunoglobulins below normal levels, and immunoparesis was severe in 18/ 166 (11%) patients (Table II) .
We assessed the impact of immunoparesis on survival outcomes. There were 108 deaths. Infection was reported as a cause of death in 8 cases. Other reported causes included: acute leukaemia -1, gastrointestinal bleeding -2, myocardial infarction -1, renal failure -3, treatment-related -4 and progressive amyloidosis or amyloidosis in all remaining cases. Median survival for this cohort was 26Á2 months. In the intent to treat (ITT) cohort, presence of more than 1 involved organ, cardiac involvement, abnormal NT-proBNP and high monoclonal FLC levels were factors adversely affecting survival by univariate analysis, and trended towards significance in multivariate analysis; whereas the presence of an M-protein, an abnormal HLC ratio, and immunoparesis by either method had no significant impact on survival (Table III) . Median OS for patients with difference between involved and uninvolved free light chains (dFLC) levels above or below 180 mg/l was 14Á8 vs. 43Á1 months, respectively [Hazard Ratio (HR) (95% confidence interval, CI): 1Á6 (1Á0-2Á4); P = 0Á05], whereas median survival for patients with severe HLC immunoparesis was 14Á8 months compared to 28Á0 months for all other patients [HR: 1Á4 (0Á9-2Á3); P = 0Á16] (Fig 1A-C) . We further assessed the survival characteristics of 121 patients who presented with cardiac involvement. In multivariate analysis, more than 1 organ affected, dFLC > 180 mg/l and severe HLC immunoparesis were associated with poorer survival (Table III) . Median OS for this cardiac population was 14Á8 months. Median OS for dFLC > 180 mg/l vs. dFLC < 180 mg/l was 12Á6 and 35Á1 months, respectively [HR: 1Á7 (1Á0-2Á9); P = 0Á04]; and severe HLC immnoparesis versus all other patients was 8Á8 and 21 months, respectively [HR: 1Á7 (1Á0-2Á9); P = 0Á06] (Fig 1D-F) . Severe immunoparesis, as determined by total Ig measurements, had no impact on prognosis in cardiac patients (P = 0Á81; Table III) .
We carried out a landmark analysis of 127 patients who survived for at least 6 months (Table III, Fig 2) . Median survival for this population was 40Á9 months. Cox regression and Kaplan-Meier analysis revealed organ involvement and dFLC levels were no longer associated with outcome in this cohort. There was a suggestion that patients with severe HLC suppression had a trend towards poorer survival (P = 0Á09). Indeed, in patients with cardiac involvement, in the 6-month landmark analysis, severe HLC suppression [HR: 2Á4 (1Á2-4Á6); P = 0Á009] was the only variable associated with shorter OS. Landmark analyses at 9 and 12 months of patients with cardiac involvement and HLC suppression also demonstrated association with survival, with median OS of 58Á5 and 63Á7 months for those with mild/no HLC suppression at 9 and 12 months, respectively, compared to 28Á4 months for those with severe HLC suppression (P = 0Á111 and P = 0Á059 respectively; Figure S1) . A tentative survival model including dFLC > 180 mg/l and severe HLC suppression as risk factors in patients with cardiac involvement stratified the population into three categories with none (n = 49), one (n = 59) and two (n = 13) risk factors and median survival times of 35Á1, 12Á7 and 8Á8 months, respectively (P = 0Á023) (Fig 3) .
Discussion
The impact of immunoparesis on outcomes in plasma cell dyscrasias has been studied and debated for many years, but only recently has been specifically assessed in AL amyloidosis.
Here we report that immunoparesis is common in systemic AL amyloidosis by both standard nephelometric Ig measurements and as determined by HLC immunoassays. Our main finding indicates that severe immunoparesis, measured by HLC immunoassay but not by total Ig measurements, is a marker of poor prognosis particularly in patients with cardiac amyloidosis who survive the first few months after therapy. Impact of M-Ig on outcomes in AL amyloidosis is unclear. The Mayo group reported that response to treatment, as determined by FLC but not by intact M-Ig, impacted survival in AL, both in chemotherapy and transplant settings (Kumar et al, 2010 (Kumar et al, , 2011 ) -data which was confirmed by a collaborative study defining response criteria in AL amyloidosis . The current cohort confirms these findings; where the presence of an M-Ig by IFE had no prognostic value. Traditional electrophoretic methods lack sensitivity for detecting M-Ig and cannot accurately quantify the low levels typically encountered in patients with systemic AL amyloidosis (Lachmann et al, 2003; Harding et al, 2010) . In patients with multiple myeloma, extreme abnormality of the HLC ratio at presentation (<0Á01 or >200) was associated with shorter time to disease progression in Intergroupe Francophone du My elome 2005-01MM trial patients . It also associates with shorter progressionfree survival and OS (Koulieris et al, 2012; Bradwell et al, 2013) . The suppression of the uninvolved Ig of the same heavy chain isotype appears to be a major contributor to this prognostic impact; it also predicts for shorter time to progression in MGUS (Katzmann et al, 2013) .
Unlike myeloma, extreme HLC ratios are rarely seen in AL amyloidosis. By contrast, immunoparesis is nearly universal in myeloma and seen in a proportion of patients with Table III . Cox regression analysis of risk factors for overall survival.
All patients
Patients with heart involvement and/or NTproBNP >332 ng/l OS 6-month landmark OS OS 6-month landmark OS (n = 163) (n = 127) (n = 121) (n = 89)
CI, confidence interval; dFLC, difference between involved and uninvolved free light chains; FLC, free light chain; HLC, heavy+light chain; HR, hazard ratio; IFE, immunofixation electrophoresis; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; OS, overall survival. P values <0.1 in bold indicate a trend towards statistical significance. monoclonal gammopathy of undetermined significance (MGUS) (Katzmann et al, 2013) . However, systemic immunoparesis, as determined by total Ig measurements, remains an inconsistent risk factor both in MGUS and MM (Cesana et al, 2002; Katzmann et al, 2013; Kastritis et al, 2014; Turesson et al, 2014) . We found a greater incidence of HLC suppression (85%) over total Ig immunoparesis (69%) in AL amyloidosis. Differences may partly be due to the ability of HLC immunoassays to separately identify the kappa and lambda isotypes of each Ig class, unlike total Ig measurements. An increased frequency of HLC suppression was also reported in a study in MGUS, in which 27% and 11% of 999 patients displayed immunoparesis as determined by HLC and total Ig measurements, respectively (Katzmann et al, 2013) . We found no correlation between Ig suppression and NTproBNP or monoclonal FLC levels, indicating that polyclonal Ig levels do not associate with other risk factors or stage of disease in AL amyloidosis (Sachchithanantham et al, 2014) . Baseline level of dFLC was prognostic in this cohort, as reported previously by other studies in AL amyloidosis (Goodman et al, 2005; Palladini et al, 2012) -the absolute value of the amyloidogenic protein was directly linked with prognosis. However, in the landmark analysis of survivors at 6 months, the dFLC lacked prognostic power. The biggest challenge in AL amyloidosis is early deaths due to diseaserelated complications. Patients surviving beyond 6 months have demonstrated resilience of organ function and have much better outcomes (Wechalekar et al, 2013) . Baseline biomarkers do not have the same prognostic impact on the 6 months survivors . The impact of baseline dFLC on survivors (or indeed the lack of prognostic impact of baseline dFLC on survivors as seen here) has, to the best of our knowledge, never been previously reported.
HLC Suppression in AL Amyloidosis
The striking observation in this series was the impact of severe HLC immunoparesis specifically on patients with cardiac involvement in a landmark analysis. Cardiac involvement remains the major prognostic determinant in AL patients and risk-adapted strategies have been suggested whereby the aggressiveness of the treatment regimen is inversely proportional to the extent of cardiac disease, as determined by cardiac biomarkers (Gertz et al, 2004b; ). There is a high likelihood that the gentler regimes are not able to achieve a deep clonal response and hence are less efficient in allowing polyclonal Ig recovery -a feature associated with improved outcomes in myeloma (Tovar et al, 2012; Harutyunyan et al, 2016; Ludwig et al, 2016; Gonzalez-Calle et al, 2017) ; or whether there is higher risk of opportunistic infections or related complications contributing to mortality in a compromised cardiovascular patient. In this context, it would be relevant to assess whether novel therapies with bortezomib-and immunomodulatory-based regimens may overcome the adverse effect of HLC immunoparesis through more efficient targeting of the clone and a boost to polyclonal immune activation (Zamarin et al, 2013; Ravi et al, 2017) .
By contrast, immunoparesis by total Ig measurement (even severe immunoparesis), had no impact on prognosis in this study. A recent report from the Mayo group showed that classical immunoparesis is prognostic in AL amyloidosis (Muchtar et al, 2016a (Muchtar et al, , 2017 . The same group previously reported no association between immunoparesis and outcome in a small cohort of 41 AL amyloidosis patients (Muchtar et al, 2016b) , intimating that sample size may account in part for the discrepant results between studies; and that the sensitivity of Hevylite assays may be potentially greater in detecting this effect, although the Mayo study did not include HLC assessments.
The impact of immunoparesis in AL patients with renal involvement requires careful interpretation, as patients with nephrotic syndrome lose IgG into the urine as a result of increased glomerular permeability. In these cases, immunoparesis may reflect IgG loss rather than plasma cell suppression (Kaysen & al Bander, 1990) . Similar to what has been described in patients with moderate immunoparesis in other series (Muchtar et al, 2017) this may explain why moderate HLC suppression did not associate with outcome in our patients.
The mechanism of suppression of normal Ig components in plasma cell dyscrasias in AL remains poorly understood but is likely to be directly related to the characteristics of the bone marrow plasma cell clone. Paiva et al (2011) reported that the presence of <5% normal plasma cells, defined by multiparameter flow cytometry, conferred a poor prognosis. Similarly, we reported that presence of >10% normal plasma cells in the marrow by flow cytometry, irrespective of absolute plasma cell percentage by morphology (also a prognostic factor as reported by the Mayo group), predicted for better outcomes . Given that normal Ig production is from persisting normal plasma cells in the bone marrow, the suppression of normal Igs, as determined by HLC, possibly represents the serum manifestation of this phenomenon. We are planning a further study of HLC correlating serum findings with baseline bone marrow assessments to confirm these observations. Whilst this study shows the important prognostic impact of HLC immunoparesis on outcomes in AL amyloidosis, the reason for this prognostic impact is far more challenging to dissect out. Infections and worsening heart failure are the commonest causes of serious adverse events in patients with AL amyloidosis undergoing chemotherapy . Drugs commonly used in treatment of AL amyloidosis, such as dexamethasone or cyclophosphamide, are excellent immunosuppressive agents and are likely to eliminate normal plasma cells in addition to achieving the desired impact of clonal eradication. Given that HLC immunoparesis of the non-clonal uninvolved Ig is most likely to be directly linked to greater suppression/depletion of normal plasma cells, it is tempting to speculate that such patients with severe HLC immunoparesis will have worsening immunodeficiency during treatment; which could tip these patients into a longer term state of immunodeficiency. The prognostic impact of HLC immunosuppression is greatest soon after completing therapy (i.e. in the 6 months landmark analysis) compared to patients alive at 9 or 12 months, suggesting that there might be immune recovery in the survivors; thereby mitigating the prognostic impact of immunoparesis. This immunoparesis may not only predispose to infective complication but may be a marker for poorer immune surveillance, which may impact the longer term outcomes in plasma cell dyscrasia. An alternative, or even concurrent, reason may be that the suppression of normal plasma cells is a direct marker for the aggressiveness of the plasma cell clone as impacting on treatment responsiveness and possible persistence of minimal residual disease (MRD) with the attendant longer term consequences. We recently reported the persistence of MRD in AL amyloidosis patients in a serological CR (Coyne et al, 2015) , highlighting the difficulty of eradicating even a small clone. We hope that an ongoing serial study of HLC monitoring in AL patients during and after treatment may address some of these questions.
This study has limitations and these observations need to be validated in a larger patient population treated with novel agents. The availability of baseline sera stored at the requisite temperatures dictated patient inclusion in this study. Baseline troponin measurement was not part of standard patient assessment at the UK NAC at time of this study and hence we are unable to present this data. We plan to expand this study to include HLC as part of baseline assessments in patients included in our ongoing observational study (ALCHemy) to validate these findings in a series of prospectively observed patient cohorts. Similarly, the retrospective nature of the data limits the ability to assess cause of death and impact, if any, of infections due to immunoparesis, which is particularly worsened after chemotherapy.
In summary, immunoparesis as defined by HLC suppression and total Ig measurements is a relatively common occurrence in AL amyloidosis. Severe HLC immunoparesis appears to be a marker of poor prognosis in patients with cardiac amyloidosis and is a particularly powerful marker in survivors beyond the first 6 months from diagnosis. The clinical benefit of routine HLC measurements in patients with AL amyloidosis warrants further exploration in larger longitudinal studies.
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